- News in Brief
- Published:
Nature Biotechnology
volume 43, page 463 (2025)Cite this article
Amgen invests $200 million in a new technology center in southern India and plans to invest further in the future to strengthen its operations and R&D capabilities. The site in Hyderabad currently employs 300 people, with plans for 1,700 more recruits skilled in data analytics, AI and digital health technologies.
The Canadian government cancels a deal with US-based Novavax to buy millions of doses of a COVID-19 vaccine that was to be made in a new biologics manufacturing facility in Montreal. It would have been the first to be produced in Canada. Novavax says the cause is the company not receiving regulatory approval by the end of 2024 for its COVID-19 vaccine using bulk antigen produced at the facility.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Biotech news from around the world.
Nat Biotechnol 43, 463 (2025). https://doi.org/10.1038/s41587-025-02643-7
Download citation
-
Published:
-
Issue Date:
-
DOI: https://doi.org/10.1038/s41587-025-02643-7
English